A new membership program, SmartRx, offers consumers savings on prescriptions, as well as office visits, eye care, vaccines and pet meds.
A new prescription discount card, SmartRx, a division of Smarty, joins GoodRx and SingleCare in the prescription discount card arena. SmartRx offers its users a free discount card and a paid membership program. The SmartRx Discount Card helps consumers save up to 80% on their prescription drugs. SmartRx+ is a monthly membership program that offers rebates for doctor or dentist visits, telehealth care, prescription glasses or contacts, annual vaccines, and pet medications.
Vipin Porwal
“An increase in healthcare costs over the past few years coupled with this past year’s inflation rates have really affected consumer’s bottom line. SmartRx is a smart healthcare cost saving solution that goes beyond prescription drug costs to help tackle these consumer concerns about health care costs,” Vipin Porwal, chief executive officer and founder of Smarty and SmartRx, told Formulary Watch.
SmartRx works with PBMs to pass on discounts when consumers present their SmartRx coupon or discount card at the pharmacy, Porwal said.
The membership rate for SmartyRx+ is $19 per month after a seven-day trial for $3. Users get a $15 cashback bonus rebate on their first prescription purchase, plus $30 annual rebate for vaccines, $50 a month for doctor and dental visits, $125 for annual for prescription glasses and contacts, $25 a month for pet medications, and other rebates.
In addition, the SmartRx Discount Card is accepted at more than 65,000 pharmacies nationwide.
In a recent SmartRx survey, 66% of respondents agreed or strongly agreed that prescriptions are too costly. Nearly half (48%) of respondents said they would use a subscription service that offers cashback and rebates on prescriptions.
Smarty is an online shopping destination that automatically applies the best coupon on purchases from more than 6,000 U.S. retailers and 1,500 global merchants.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More